AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
Executive Summary
AbbVie's JAK1 inhibitor upadacitinib bested the company's blockbuster Humira in the largest and longest trial to date – on both efficacy and safety – perhaps alleviating concerns about cardiovascular events.
You may also be interested in...
First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
While You Were Out: News In Brief
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.